Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

It has been about a month since the last earnings report for AtaiBeckley Inc (ATAI). Shares have added about 0.8% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is AtaiBeckley Inc due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for AtaiBeckley Inc before we dive into how investors and analysts have reacted as of late.

AtaiBeckley Q2 Loss Narrower Than Expected

AtaiBeckley reported a loss of 9 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, the company had reported a loss of 14 cents.

The company reported revenues of $1.7 million in the second quarter of 2026, down 142.8% year over year. Revenues comprised license revenues and research and development services revenues.

Quarter in Detail

Research and development expenses rose 153% year over year to $28.1 million in the second quarter, owing to higher clinical development costs and increased personnel-related costs.

General and administrative expenses in the second quarter were $17.8 million, up 19.5% year-over-year due to increased legal, intellectual property and professional service expenses.

As of June 30, 2026, AtaiBeckley had cash, cash equivalents and marketable securities worth $191.8 million compared with $209.9 million as of March 31, 2026.

How Have Estimates Been Moving Since Then?

It turns out, estimates revision have trended downward during the past month.

VGM Scores

Currently, AtaiBeckley Inc has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. However, the stock has a score of F on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, AtaiBeckley Inc has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

AtaiBeckley Inc belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Rocket Pharmaceuticals (RCKT), has gained 6.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Rocket Pharmaceuticals reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.15 for the same period compares with -$0.59 a year ago.

For the current quarter, Rocket Pharmaceuticals is expected to post a loss of $0.38 per share, indicating a change of +15.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +6.8% over the last 30 days.

Rocket Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research